Abstract
The ubiquitous distribution of vitamin D receptors in the human body is responsible for the pleiotropic effects of vitamin D-receptor activation. We discuss the possible beneficial effects of a selective activator of vitamin D receptor, paricalcitol, on the cardiovascular system in chronic heart failure patients and chronic kidney patients, in light of new trials. Paricalcitol should provide additional clinical benefits over the standard treatment for chronic kidney and heart failure, especially in cases of cardiorenal syndrome.
Keywords:
albuminuria; cardiovascular system; inflammation; vitamin D deficiency.
MeSH terms
-
Aging / physiology*
-
Animals
-
Bone Density Conservation Agents / pharmacology
-
Bone Density Conservation Agents / therapeutic use*
-
Cardio-Renal Syndrome / drug therapy
-
Cardio-Renal Syndrome / physiopathology
-
Cardiovascular System / drug effects
-
Chronic Disease
-
Ergocalciferols / pharmacology
-
Ergocalciferols / therapeutic use*
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Randomized Controlled Trials as Topic
-
Receptors, Calcitriol / agonists*
-
Renal Insufficiency, Chronic / drug therapy*
-
Renal Insufficiency, Chronic / physiopathology
Substances
-
Bone Density Conservation Agents
-
Ergocalciferols
-
Receptors, Calcitriol
-
paricalcitol